An observational study in Influenza, sponsored by Ab&B Bio-tech Co., Ltd.JS. Recruiting at 1 site in China. Open to participants aged 6 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Ab&B Bio-tech Co., Ltd.JS · Observational
Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.
Among the 173 studies in Influenza, Human with a site in China, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 15 that started in 2026, is one of 14 observational ones, reaches primary completion later than 26 of the 36 other live ones, and was the 173rd registered.
2,358 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Shanghai Institute Of Biological Products · Sites in China
Ages 60+ · Healthy volunteers
Capital Medical University · Sites in China
Ages 12+
Ruijin Hospital · Sites in China
Ages 12–17
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 120 Influenza, Human studies recruiting now, 64 (53%) set no upper age limit and 46 (38%) stop at 75 or younger; 33 take children under 18; 66 take healthy volunteers.
This study: 6 Months and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 22 · Phase 3 49 · Phase 4 43
First in 2004; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 7,000 is above the median of 397 across 334 observational studies indexed under Influenza, Human.
Median enrollment 360 across the 157 interventional studies, 230 across the 14 observational. Of the 115 that completed or were terminated, 9 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 173 have an industry lead sponsor. The 10 most frequent:
Ab&B Bio-tech Co., Ltd.JS is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Ab&B Bio-tech Co., Ltd.JS has 7 studies filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
14 of the studies in Influenza, Human with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229547Phase 3Ruijin HospitalA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A. | 2026-12-01 |
| NCT07236814Phase 3Capital Medical UniversitySuraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting | 2027-03-01 |
| NCT07893847Phase 3Capital Medical UniversityEvaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza | 2027-03-30 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06574503Phase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | 2027-07-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 173 studies in Influenza, Human with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a post-marketing, prospective observational study to evaluate the safety of a subunit influenza vaccine and the factors influencing influenza vaccination in individuals aged 6 months and older. A total of 7,000 vaccinated participants will be divided into Subgroup A (1,000 participants, active surveillance) and Subgroup B (6,000 participants, passive surveillance), and monitored for adverse events and serious adverse events within 28 days after vaccination. Participants in Subgroup A will additionally complete an electronic questionnaire on their knowledge of influenza and factors influencing their vaccination decisions.
Study Objectives The primary objectives of this study are: (1) to evaluate the safety of the subunit influenza vaccine in individuals aged 6 months and older after vaccination, in order to assess the occurrence of adverse reactions; and (2) to investigate vaccinated individuals' knowledge of influenza and influenza vaccine, and the factors influencing their vaccination decisions.Study Design This is a post-marketing, prospective, open-label, single-arm observational study. Participants who have already received the subunit influenza vaccine at the study site will be enrolled and divided into two subgroups according to the surveillance mode: Subgroup A (1,000 participants) under active surveillance, and Subgroup B (6,000 participants) under passive surveillance. All participants will be observed for 30 minutes after vaccination and monitored for adverse events (AEs) and serious adverse events (SAEs) within 28 days after vaccination.Study Population Individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and are able to comply with the study requirements. Participants with allergy to any vaccine component (including excipients, formaldehyde, or Triton N-101), acute illness, severe chronic disease, acute exacerbation of chronic disease, fever, uncontrolled epilepsy, other progressive neurological diseases, a history of Guillain-Barré syndrome, or a history of severe adverse reactions to previous influenza vaccination will be excluded.Safety Monitoring All participants will remain under observation for 30 minutes immediately after vaccination. The occurrence of AEs and SAEs within 28 days post-vaccination will be collected and recorded, including solicited local reactions (pain, swelling, erythema, pruritus, induration, ecchymosis) and systemic events (fever, cough, headache, rhinorrhea, fatigue, myalgia, arthralgia, gastrointestinal symptoms, rash, etc.). Subgroup A participants will receive a telephone follow-up on Day 28, while Subgroup B participants will self-report AEs to investigators during the same period. Any SAE will be reported in accordance with applicable regulations.Influencing Factor Survey Participants in Subgroup A will complete an electronic questionnaire during the post-vaccination observation period (by themselves if aged 18 years or older, or by their guardians if under 18), collecting demographic information, medical and vaccination history, and their knowledge of influenza and influenza vaccine, as well as the factors influencing their vaccination decisions.
Healthy individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and meet the eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Surveillance Group
Biological: Group A
Passive Surveillance Group
Biological: Group B
Participants will receive one dose of Subunit Influenza Vaccine
Participants will receive one dose of Subunit Influenza Vaccine
Occurrence of AEs and ADRs
Adverse events and adverse drug reactions occurring within 28 days of vaccination will be recorded, including solicited local and systemic reactions.
Time frame: Within 28 days post-vaccination
Occurrence of SAEs
Serious adverse events occurring within 28 days of vaccination will be recorded.
Time frame: Within 28 days post-vaccination
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.
Of 98 non-industry observational studies under Influenza, Human, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 92. This study's planned 6 months is below that.
Counting every sponsor, half of 135 studies reached it within 23 months; a quarter within 7 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ab&B Bio-tech Co., Ltd.JS